Sumitomo Mitsui Trust Group Inc. Acquires 699,925 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 93.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,450,416 shares of the company's stock after acquiring an additional 699,925 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 3.13% of Omnicell worth $64,573,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after buying an additional 553 shares in the last quarter. Curi RMB Capital LLC raised its holdings in Omnicell by 0.7% in the 3rd quarter. Curi RMB Capital LLC now owns 88,815 shares of the company's stock worth $3,872,000 after acquiring an additional 651 shares during the period. KBC Group NV raised its holdings in Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock worth $92,000 after acquiring an additional 778 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Omnicell by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company's stock worth $635,000 after acquiring an additional 1,360 shares during the period. Finally, 1620 Investment Advisors Inc. raised its holdings in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after acquiring an additional 1,542 shares during the period. Institutional investors own 97.70% of the company's stock.

Insider Activity

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on OMCL shares. Bank of America dropped their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Wells Fargo & Company lowered their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. upped their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Finally, Craig Hallum upped their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $52.33.

Omnicell Trading Down 0.7 %

NASDAQ:OMCL traded down $0.27 during trading hours on Thursday, hitting $40.22. 306,492 shares of the stock were exchanged, compared to its average volume of 408,772. The company has a market capitalization of $1.86 billion, a P/E ratio of 148.97, a price-to-earnings-growth ratio of 26.98 and a beta of 0.78. The company has a quick ratio of 0.95, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The company's 50 day moving average is $43.89 and its two-hundred day moving average is $43.63. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, sell-side analysts anticipate that Omnicell, Inc. will post 1.04 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.